Standard Biotools (LAB) Total Current Liabilities (2010 - 2026)

Standard Biotools (LAB) has 17 years of Total Current Liabilities data on file, last reported at $42.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 24.95% year-over-year to $42.2 million in Q1 2026; TTM through Mar 2026 was $42.2 million, a 24.95% decrease from a year earlier, with the FY2025 full-year figure at $108.3 million, up 64.36% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $42.2 million, down from $108.3 million in the prior quarter.
• Over the last five years, Total Current Liabilities for LAB reached as high as $123.8 million in Q2 2024 and fell as low as $42.2 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $75.1 million across 5 years, with a median of $56.2 million in 2025.
• Across the five-year window, Total Current Liabilities jumped 177.6% in 2024 and tumbled 53.74% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $43.4 million in 2022, then jumped by 151.66% to $109.3 million in 2023, then tumbled by 39.73% to $65.9 million in 2024, then soared by 64.36% to $108.3 million in 2025, then slumped by 61.03% to $42.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $42.2 million in Q1 2026, $108.3 million in Q4 2025, and $108.0 million in Q3 2025.